BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
BMP4 工程间充质干细胞治疗胶质母细胞瘤
基本信息
- 批准号:9065529
- 负责人:
- 金额:$ 33.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-08 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdherenceAdipose tissueAdjuvant RadiotherapyAdultAffectAgeAllogenicAnimalsAntineoplastic AgentsApoptosisAutologousBlood - brain barrier anatomyBone MarrowBrainBrain NeoplasmsCellsCharacteristicsClinicalClinical TrialsDevicesEffectivenessEndotheliumEngineeringExcisionFutureGlioblastomaGliomaGoalsGrantHealthHumanImmuneImmunotherapeutic agentIn VitroInvadedInvestigationLeadLocal TherapyLongevityMalignant NeoplasmsMalignant neoplasm of brainMesenchymal Stem CellsMicrofluidicsModelingMorbidity - disease rateMusNatureOncogenicOperative Surgical ProceduresPatientsPlaguePrimary Brain NeoplasmsProteinsRadiationRadiation therapyRadioReactionRecurrenceResearchResearch DesignResistanceSafetySourceStem cellsSurfaceSurvival RateTargeted RadiotherapyTechniquesTestingTherapeuticTherapeutic EffectTranslatingTropismTumor BurdenTumor EscapeViralXenograft Modelbone morphogenic proteinbrain parenchymacancer cellcancer typecell motilitycellular engineeringchemoradiationclinical applicationeffective therapygenetically modified cellsimplantationin vivoin vivo Modelineffective therapiesmigrationmortalitymouse modelnanobiotechnologyneoplastic cellnovelnovel therapeuticsresearch studyresponsestem cell therapytargeted deliverytreatment strategytumortumorigenic
项目摘要
DESCRIPTION (provided by applicant): Glioblastoma (GBM) is the most common primary brain tumor in adults, and accounts for 20% of all primary brain tumors. GBM has a median survival rate of only 14.6 months despite current best treatment practices which include surgery and chemoradiation. A significant reason for this morbidity and mortality is the ability of GBM to invade normal brain parenchyma, making localized treatment ineffective. In order for treatment to be effective, these invading cells need to be targeted. One promising approach involves the use of mesenchymal stem cells (MSCs), which have been found by our group and by others to migrate preferentially to cancer cells. Moreover, MSCs can be engineered to synthesize and release anti-tumor proteins, such as bone morphogenic protein 4 (BMP4), which has been found to affect brain tumor initiating cells (BTICs). MSCs can be obtained from bone marrow (BM-MSC) and adipose tissue (AMSC). The use of BM-MSCs has been limited because these cells are difficult to obtain, have limited ex vivo proliferation capacity, and decrease in effectiveness with increasing donor age. AMSCs may therefore be a better option. In this grant, we propose to use a novel source for human MSCs, adipose tissue from our patients, and genetically modify these cells to secrete BMP4 for the treatment of GBM. In contrast to BM-MSCs, human AMSCs (hAMSCs) provide a therapeutically comparable source of cells which are more readily accessible and have better ex vivo expansibility. Our overall hypothesis is that virally-modified hAMSCs expressing BMP4 in combination with adjuvant radiotherapy constitute an effective treatment against intracranial GBM. To achieve these goals, we will pursue the following specific aims: (Aim 1) To determine the tumor tropism, endothelial adherence, blood brain barrier crossing capability, and anti-glioma response of virally-modified BMP4-secreting primary hAMSCs in vitro-we have shown this with commercial hAMSCs and we propose to do it now with Freshly extracted Adipose Tissue (F.A.T.); (Aim 2) To determine the safety and efficacy of virally-modified BMP4-secreting hAMSCs in combination with targeted radiation therapy on human GBM in an in vivo murine model. The techniques to be used in vitro and in vivo in this proposal have been developed and further characterized by our team and by our collaborators. In vitro studies will be conducted using new advancements in the fields of microfluidics and nanobiotechnology. In vivo studies will employ a mammalian xenograft model that engrafts human BTIC- derived GBM, which bests recapitulates human GBM. Additionally, we will use the small animal radiation research platform (SARRP), a novel device developed and used by our team and collaborators, which allows the delivery of targeted beams of radiation therapy to tumor-bearing mice analogous to confocal beam therapy in humans. The SARRP is capable of focusing a beam of radiation with an accuracy of 0.2 mm, recreating radiotherapy for humans on the scale of a mouse. In addition to our experiments on commercial hAMSCs, we will obtain primary hAMSCs intraoperatively from human patients and test their anti-tumor efficacy to maximize the clinical translatability of this study. The results of this stuy will demonstrate whether hAMSCs can provide a treatment that is safe and effective for not only patients with GBM, but many types of primary and metastatic brain cancers. The results of this study may likely lead to clinical trials, with a revolutionary new way of treating patients with brin cancer.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALFREDO QUINONES-HINOJOSA其他文献
ALFREDO QUINONES-HINOJOSA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALFREDO QUINONES-HINOJOSA', 18)}}的其他基金
A Bioprinted Volumetric Model of Vascularized Glioblastoma
血管化胶质母细胞瘤的生物打印体积模型
- 批准号:
10717766 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
BMP4 工程间充质干细胞治疗胶质母细胞瘤
- 批准号:
9188284 - 财政年份:2015
- 资助金额:
$ 33.35万 - 项目类别:
Role of NKCC1 on Brain Tumor Stem Cell Migration After EGF and Slit-2 Stimulation
EGF 和 Slit-2 刺激后 NKCC1 对脑肿瘤干细胞迁移的作用
- 批准号:
8660402 - 财政年份:2013
- 资助金额:
$ 33.35万 - 项目类别:
Role of NKCC1 on Brain Tumor Stem Cell Migration After EGF and Slit-2 Stimulation
EGF 和 Slit-2 刺激后 NKCC1 对脑肿瘤干细胞迁移的作用
- 批准号:
8436280 - 财政年份:2010
- 资助金额:
$ 33.35万 - 项目类别:
Role of NKCC1 on Brain Tumor Stem Cell Migration After EGF and Slit-2 Stimulation
EGF 和 Slit-2 刺激后 NKCC1 对脑肿瘤干细胞迁移的作用
- 批准号:
8625346 - 财政年份:2010
- 资助金额:
$ 33.35万 - 项目类别:
Role of NKCC1 on Brain Tumor Stem Cell Migration After EGF and Slit-2 Stimulation
EGF 和 Slit-2 刺激后 NKCC1 对脑肿瘤干细胞迁移的作用
- 批准号:
8257549 - 财政年份:2010
- 资助金额:
$ 33.35万 - 项目类别:
Role of NKCC1 on Brain Tumor Stem Cell Migration After EGF and Slit-2 Stimulation
EGF 和 Slit-2 刺激后 NKCC1 对脑肿瘤干细胞迁移的作用
- 批准号:
8088160 - 财政年份:2010
- 资助金额:
$ 33.35万 - 项目类别:
Role of NKCC1 on Brain Tumor Stem Cell Migration After EGF and Slit-2 Stimulation
EGF 和 Slit-2 刺激后 NKCC1 对脑肿瘤干细胞迁移的作用
- 批准号:
7865447 - 财政年份:2010
- 资助金额:
$ 33.35万 - 项目类别:
Migration of Human Neural Stem Cells In Vitro and In Vivo
人类神经干细胞的体外和体内迁移
- 批准号:
7907627 - 财政年份:2006
- 资助金额:
$ 33.35万 - 项目类别:
Migration of Human Neural Stem Cells In Vitro and In Vivo
人类神经干细胞的体外和体内迁移
- 批准号:
7131997 - 财政年份:2006
- 资助金额:
$ 33.35万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 33.35万 - 项目类别:
Fellowship Programs